Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Nu.Q® Discover H3.1 Kit Product Brochure

Thursday, January 11, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the Nu.Q® Discover H3.1 Kit, highlighting its prognostic value in cancer testing. It emphasizes the importance of this product in the context of ongoing research and development efforts. Related articles and resources are also mentioned, indicating a commitment to keeping stakeholders informed.
Price reaction · baseline $17.264 (2024-01-10 close) · hit pre-market · clean, no other VNRX news in the window
day 0 close · peak
-2.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • The Nu.Q® Discover H3.1 Kit shows promising prognostic value.
  • The product is part of a broader effort to advance cancer testing.

Full Press Release Details

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the Nu.Q® Discover H3.1 Kit?

The Nu.Q® Discover H3.1 Kit is a product designed for cancer testing.

What is the significance of the Nu.Q® Kit?

It shows promising prognostic value in assessing cancer.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare cancer test prognostic value Nu.Q® biopharma
Last updated: Jan 11, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk